Skip to main content
Top

09-07-2016 | Drug-induced diabetes | Book chapter | Article

Secondary Causes of Diabetes Mellitus

Authors: Ashutosh S. Pareek, Yana B. Garger, Prajesh M. Joshi, Carla M. Romero, Amit K. Seth

Publisher: Springer International Publishing

Abstract

The diabetic syndromes include type 1 diabetes with immune destruction of the pancreatic islets, type 2 diabetes with a complex pathophysiology of insulin resistance combined with insulin secretory failure, distinct monogenetic abnormalities (maturity onset diabetes of the young – MODY), and extreme insulin resistance of several different etiologies. In addition, secondary causes of diabetes mellitus refer to a category in which diabetes is associated with other diseases or conditions related to both the endocrine and exocrine pancreas and other secretory organs of the body. In some instances, diabetes is due to genetic syndrome or use of medicines. Presumably, the diabetes is caused by those conditions or medicines and could be reversed if those conditions were cured.
Literature
1.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2008;31 Suppl 1:S55–60.CrossRef
2.
Pitchumoni CS, Patel NM, Shah P. Factors influencing mortality in acute pancreatitis. J Clin Gastroenterol. 2005;39:798–814.PubMedCrossRef
3.
Thow J, Semad A, Alberti KGMM. Epidemiology and general aspects of diabetes secondary to pancreatopathy. In: Tiengo A, Alberti KGMM, Del Prato S, Vranic M, editors. Diabetes secondary to pancreatopathy. Amsterdam: Excerpta Medica; 1988. p. 7–20.
4.
Del Prato S, Tiengo A. Diabetes secondary to acquired disease of the pancreas. In: Alberti KGMM, DeFronzo RA, Keen H, Zimmet P, editors. International textbook of diabetes mellitus. New York: Wiley; 1992. p. 199.
5.
Ueda T, Takeyama Y, Yasuda T, et al. Simple scoring system for the prediction of the prognosis of severe acute pancreatitis. Surgery. 2007;141:51–8.PubMedCrossRef
6.
Drew SI, Joffe B, Vinik AI, et al. The first 24 hours of acute pancreatitis. Changes in biochemical and endocrine homeostasis inpatients with pancreatitis compared to those in control subjects undergoing stress for reasons other than pancreatitis. Am J Med. 1978;64:795–803.PubMedCrossRef
7.
Donowitz M, Hendeler R, Spiro HM, et al. Glucagon secretion in acute and chronic pancreatitis. J Intern Med. 1975;83:778–81.
8.
Kaya E, Dervisoglu A, Polat C. Evaluation of diagnostic findings and scoring systems in outcome prediction in acute pancreatitis. World J Gastroenterol. 2007;13(22):3090–4.PubMedPubMedCentral
9.
Andersen DK. Mechanisms and emerging treatments of the metabolic complications of chronic pancreatitis. Pancreas. 2007;35(1):1–15.PubMedCrossRef
10.
Mlka D, Hammel P, Sauvanet A, et al. Risk factors for diabetes mellitus in chronic pancreatitis. Gastroenterology. 2000;119:1324–32.CrossRef
11.
Angelopoulos N, Dervenis C, Goula A, et al. Endocrine pancreatic insufficiency in chronic pancreatitis. Pancreatology. 2005;5:122–31.PubMedCrossRef
12.
Larsen S. Diabetes mellitus secondary to chronic pancreatitis. Dan Med Bull. 1993;40(2):153–62.PubMed
13.
Hedetoft C, Sheikh SP, Larsen S, Holst JJ. Effect of glucagons-like peptide 1(7–36)amide in insulin-treated patients with diabetes mellitus secondary to chronic pancreatitis. Pancreas. 2000;20(1):25–31.PubMedCrossRef
14.
Mergener K, Baillie J. Chronic pancreatitis. Lancet. 1997;350:1379–85.PubMedCrossRef
15.
Chari ST, Leibson CL, Rabe KG, et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology. 2008;134:95–101.PubMedPubMedCentralCrossRef
16.
Murat S, Parviz PM. Diabetes and its relationship to pancreatic carcinoma. Pancreas. 2003;26(4):381–7.CrossRef
17.
Hull RL, Westermark GT, Westermark P, Kahn SE. Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J Clin Endocrinol Metab. 2004;89:3629–43.PubMedCrossRef
18.
Casas S, Gomis R, Gribble FM, et al. Impairment of the ubiquitin–proteasome pathway is a downstream endoplasmic reticulum stress response induced by extracellular human islet amyloid polypeptide and contributes to pancreatic β-cell apoptosis. Diabetes. 2007;56:2284–94.PubMedCrossRef
19.
Permert J, Larsson J, Fruin AB, et al. Islet hormone secretion in pancreatic cancer patients with diabetes. Pancreas. 1997;15:60–8.PubMedCrossRef
20.
Slezak LA, Andersen DK. Pancreatic resection: effects on glucose metabolism. World J Surg. 2001;25:452–60.PubMedCrossRef
21.
Brennan AL, Geddes DM, Gyi KM, Baker EH. Clinical importance of cystic fibrosis-related diabetes. J Cyst Fibros. 2004;3(4):209–22.PubMedCrossRef
22.
Dobson L, Stride A, Bingham C, et al. Microalbuminuria as a screening tool in cystic fibrosis-related diabetes. Pediatr Pulmonol. 2005;39(2):103–7.PubMedCrossRef
23.
Shwachman H, Kowalski M, Khaw KT. Cystic fibrosis: a new outlook, 70 patients above 25 years of age. Medicine. 1977;56:24–49.CrossRef
24.
Alves Cde A, Aguiar RA, Alves AC, Santana MA. Diabetes mellitus in patients with cystic fibrosis. J Bras Pneumol. 2007;33(2):213–21.PubMedCrossRef
25.
Bizzarri C, Lucidi V, Ciampalini P, et al. Clinical effects of early treatment with insulin glargine in patients with cystic fibrosis and impaired glucose tolerance. J Endocrinol Invest. 2006;29(3):RC1–4.PubMedCrossRef
26.
Williams R, Williams HS, Scheuer PJ, et al. Iron absorption and siderosis in chronic liver disease. Quart J Med. 1967;35:151–66.
27.
Powell LW, Yapp TR. Hemochromatosis. Clin Liver Dis. 2000;4(1):211–28.PubMedCrossRef
28.
Wilson J, Lindquist J, Grambow S, et al. Potential role of increased iron stores in diabetes. Am J Med Sci. 2003;325(6):332–9.PubMedCrossRef
29.
Swaminathan S, Fonseca V, Alam M, Shah S. The role of iron in diabetes and its complications. Diabetes Care. 2007;30(7):1926–33.PubMedCrossRef
30.
Wermers RA, Fatourechi V, Wynne AG, et al. The glucagonoma syndrome. Medicine. 1996;75:53.PubMedCrossRef
31.
Warner R. Enteroendocrine tumors other than carcinoid: a review of clinically significant advances. Gastroenterology. 2005;128:1668–84.PubMedCrossRef
32.
Beek AP, de Haas ERM, van Vloten WA, et al. The glucagonoma syndrome and necrolytic migratory erythema: a clinical review. Eur J Endocrinol. 2004;151:531–7.PubMedCrossRef
33.
Lefgbvre PJ. Glucagon and its family revisited. Diabetes Care. 1995;18:715–30.CrossRef
34.
Vinik AI, Strodel WE, Eckhauser FE, et al. Somatostatinomas, PPomas, neurotensinomas. Semin Oncol. 1987;14:263–81.PubMed
35.
Sassolas G, Chayvialle JA. GRFomas, somatostatinomas: clinical presentation, diagnosis, and advances in management. In: Mignon M, Jensen RT, editors. Endocrine tumors of the pancreas: recent advances in research and management, Frontiers of Gastrointestinal Research, vol. 23. Basel: S. Karger; 1995. p. 194.
36.
Matuchansky C, Rambuaud JC. VIPomas and endocrine cholera: clinical presentation, diagnosis, and advances in management. In: Mignon M, Jensen RT, editors. Endocrine tumors of the pancreas: recent advances in research and management, Frontiers of Gastrointestinal Research, vol. 23. Basel: S. Karger; 1995. p. 166.
37.
McCallum RW, Parameswaran V, Burgess JR. Multiple endocrine neoplasia type 1 (MEN 1) is associated with an increased prevalence of diabetes mellitus and impaired fasting glucose. Clin Endocrinol. 2006;65:163–8.CrossRef
38.
Feldman JM, Plonk JW, Bivens CH, Levobitz HE. Glucose intolerance in the carcinoid syndrome. Diabetes. 1975;24:664–71.PubMedCrossRef
39.
Mitzner LD, Nohria A, Chacho M, Inzucchi SE. Sequential hypoglycemia, hyperglycemia, and the carcinoid syndrome arising from a plurihormonal neuroendocrine neoplasm. Endocr Pract. 2000;6:370–4.PubMedCrossRef
40.
DeFronzo RA, Ferrannini E. Regulation of hepatic glucose metabolism in humans. Diabetes Metab Rev. 1987;3:415–59.PubMedCrossRef
41.
Zein NN. Prevalence of diabetes mellitus in patients with end-stage liver cirrhosis due to hepatitis C, alcohol, or cholestatic disease. J Hepatol. 2000;32:209–17.PubMedCrossRef
42.
Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care. 2007;30(3):734–43.PubMedCrossRef
43.
Albright ES, Bell DSH. The liver, liver disease, and diabetes mellitus. Endocrinol. 2003;13(1):58–66.CrossRef
44.
Cavallo-Perin P, Cassader M, Bozzo C, et al. Mechanism of insulin resistance in human liver cirrhosis: evidence of combined receptor and postreceptor defect. J Clin Invest. 1985;75:1659–65.PubMedPubMedCentralCrossRef
45.
Harrison SA. Liver disease in patients with diabetes mellitus. J Clin Gastroenterol. 2006;40:68–76.PubMedCrossRef
46.
Holstein A, Hinze S, Thiessen E, et al. Clinical implications of hepatogenous diabetes in liver cirrhosis. J Gastroenterol Hepatol. 2002;17(6):677–81.PubMedCrossRef
47.
Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116:1793–801.PubMedPubMedCentralCrossRef
48.
Samuel VT, Liu ZX, Wang A, et al. Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease. J Clin Invest. 2007;117:739–45.PubMedPubMedCentralCrossRef
49.
Fartoux L, Poujol-Robert A, Guéchot J, et al. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut. 2005;54(7):1003–8.PubMedPubMedCentralCrossRef
50.
Hickman IJ, Macdonald GA. Impact of diabetes on the severity of liver disease. Am J Med. 2007;120(10):829–34.PubMedCrossRef
51.
Fraser GM, Harman I, Meller N, et al. Diabetes mellitus is associated with chronic hepatitis C but not chronic hepatitis B infection. Isr J Med Sci. 1996;32:526–30.PubMed
52.
Knobler H, Schihmanter R, Zifroni A, et al. Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection. Mayo Clin Proc. 2000;75:355–9.PubMedCrossRef
53.
Huang JF, Dai CY, Hwang SJ, et al. Hepatitis C viremia increases the association with type 2 diabetes mellitus in a hepatitis B and C endemic area: an epidemiological link with virological implication. Am J Gastroenterol. 2007;102(6):1237–43.PubMedCrossRef
54.
Mehta SH, Brancati FL, Strathdee SA, et al. Hepatitis C virus infection and incident type 2 diabetes. Hepatology. 2003;38(1):50–6.PubMedCrossRef
55.
Zein CO, Levy C, Basu A, Zein NN. Chronic hepatitis C and type II diabetes mellitus: a prospective cross-sectional study. Am J Gastroenterol. 2005;100(1):48–55.PubMedCrossRef
56.
Lecube A, Hernández C, Genescà J, Simó R. Glucose abnormalities in patients with hepatitis C virus infection: epidemiology and pathogenesis. Diabetes Care. 2006;29(5):1140–9.PubMedCrossRef
57.
Mehta SH, Brancati FL, Sulkowski MS, et al. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Hepatology. 2001;33(6):1554.PubMedCrossRef
58.
Hadziyannis SJ. The spectrum of extrahepatic manifestations in hepatitis C virus infection. J Vir Hepat. 1997;4:9–28.CrossRef
59.
Oben JA, Paulon E. Fatty liver in chronic hepatitis C infection: unraveling the mechanisms. Gut. 2007;56:1186–8.PubMedPubMedCentralCrossRef
60.
Knobler H, Schattner A. TNF-alpha, chronic hepatitis C and diabetes: a novel triad. QJM. 2005;98(1):1–6.PubMedCrossRef
61.
Chen LK, Chou YC, Tsai ST, et al. Hepatitis C virus infection-related type 1 diabetes mellitus. Diabet Med. 2005;22(3):340–3.PubMedCrossRef
62.
Kawaguchi T, Yoshida T, Harada M, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol. 2004;165(5):1499–508.PubMedPubMedCentralCrossRef
63.
Aytug S, Reich D, Sapiro LE, et al. Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. Hepatology. 2003;38(6):1384–92.PubMedCrossRef
64.
Romero-Gómez M, Del Mar VM, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology. 2005;128(3):636–41.PubMedCrossRef
65.
Hickman IJ, Powell EE, Prins JB, et al. In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. J Hepatol. 2003;39(6):1042–8.PubMedCrossRef
66.
Taura N, Ichikawa T, Hamasaki K, et al. Association between liver fibrosis and insulin sensitivity in chronic hepatitis C patients. Am J Gastroenterol. 2006;101(12):2752–9.PubMedCrossRef
67.
Trombetta M, Spiazzi G, Zoppini G, Muggeo M. Review article: type 2 diabetes and chronic liver disease in the Verona diabetes study. Aliment Pharmacol Ther. 2005;22 Suppl 2:24–7.PubMedCrossRef
68.
Negro F, Alaei M. Hepatitis C virus and type 2 diabetes. World J Gastroenterol. 2009;15(13):1537–47.PubMedPubMedCentralCrossRef
69.
Doyle MA, Cooper C. Successful Hepatitis C Antiviral Therapy Induces Remission of Type 2 Diabetes: A Case Report. Am J Case Rep. 2015;16:745–50.PubMedPubMedCentralCrossRef
70.
Harrison SA, Hamzeh FM, Han J, Pandya PK, Sheikh MY, Vierling JM. Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin. Hepatology. 2012;56:464–73.PubMedCrossRef
71.
Premji R, et al. New-onset diabetes mellitus with exposure to Ledipasvir and Sofosbuvir. J Invest Med High Impact Case Rep. 2015;1–2.
72.
Record CO, Alberti KG, Williamson DH, Wright R. Glucose tolerance and metabolic changes in human viral hepatitis. Clin Sci Mol Med. 1973;45:677–90.PubMed
73.
Bianchi G, Marchesini G, Zoli M, et al. Prognostic significance of diabetes in patients with cirrhosis. Hepatology. 1994;20:119–25.PubMed
74.
Vesely DL, Dilley RW, Duckworth WC, Paustian FF. Hepatitis A-induced diabetes mellitus, acute renal failure, and liver failure. Am J Med Sci. 1999;317(6):419–25.PubMedCrossRef
75.
Masuda H, Atsumi T, Fujisaku A, et al. Acute onset of type 1 diabetes accompanied by acute hepatitis C: the potential role of proinflammatory cytokine in the pathogenesis of autoimmune diabetes. Diabetes Res Clin Pract. 2007;75(3):357–61.PubMedCrossRef
76.
Luna B, Feinglos MN. Drug-induced hyperglycemia. JAMA. 2001;286(16):1945–8.PubMedCrossRef
77.
Kao WH, Puddey IB, Boland LL, Watson RL, Brancati FL. Alcohol consumption and the risk of type 2 diabetes mellitus: Atherosclerosis Risk in Communities study. Am J Epidemiol. 2001;154:748–57.PubMedCrossRef
78.
Kim SH, et al. Effect of moderate alcohol beverage consumption insulin sensitivity in insulin resistant, nondiabetic individuals. Metabolism. 2009;58(3):387–92.PubMedPubMedCentralCrossRef
79.
Wicklmayr M, Rett K, Dietze G, Mehnert H. Effects of beta-blocking agents on insulin secretion and glucose disposal. Horm Metab Res Suppl. 1990;22:29–33.PubMedCrossRef
80.
Sarafidis PJ, Bakris GL. Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control. QJM:An Int J Med. 2006;99(7):432–6.CrossRef
81.
Lambertus MW, Murthy AR, Nagami P, et al. Diabetic ketoacidosis following pentamidine therapy in a patient with the acquired immunodeficiency syndrome. West J Med. 1988;149:602–4.PubMedPubMedCentral
82.
Bouchard P, Sai P, Reach G, et al. Diabetes mellitus following pentamidine-induced hypoglycemia in humans. Diabetes. 1982;31:40–5.PubMedCrossRef
83.
Assan R, Perronne C, Assan D, et al. Pentamidine-induced derangements of glucose homeostasis. Diabetes Care. 1995;18:47–55.PubMedCrossRef
84.
Pandit MK, Burke J, Gustafson AB, et al. Drug-induced disorders of glucose tolerance. Ann Intern Med. 1993;118:529–40.PubMedCrossRef
85.
O’Byrne S, Feely J. Effects of drugs on glucose tolerance in non-insulin-dependent diabetes (parts I and II). Drugs. 1990;40:203–19.PubMedCrossRef
86.
Shiba T, Morino Y, Tagawa K, et al. Onset of diabetes with high titer anti-GAD antibody after IFN therapy for chronic hepatitis. Diabetes Res Clin Pract. 1996;30:237–41.CrossRef
87.
Gallanosa AG, Spyker DA, Curnow RT. Diabetes mellitus associated with autonomic and peripheral neuropathy after Vacor poisoning: a review. Clin Toxicol. 1981;18:441–9.PubMedCrossRef
88.
Florescu D, Kotler DP. Insulin resistance, glucose intolerance and diabetes mellitus in HIV-infected patients. Antivir Ther. 2007;12:149–62.PubMed
89.
Moyle G. Metabolic issues associated with protease inhibitors. J Acquir Immune Defic Syndr. 2007;45:S19–26.PubMedCrossRef
90.
Martinez E, Mocroft A, Garcia-Viejo MA, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet. 2001;357:592–8.PubMedCrossRef
91.
Liang J, Distler O, Cooper DA, et al. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med. 2001;7:1327–31.PubMedCrossRef
92.
Riddle TM, Kuhel DG, Woollett LA, et al. HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J Biol Chem. 2001;276:37514–9.PubMedCrossRef
93.
Martine C, Auclair M, Vigouroux C, et al. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes. 2001;50:1378–88.CrossRef
94.
Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem. 2000;275:20251–4.PubMedCrossRef
95.
American Diabetes Association. Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care. 2015;38(9):1777–803.CrossRef
96.
Cederberg H, Stancakova A, Yaluri N, Modi S, Kuusisto J, Laakso M. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort. Diabetilogia. 2015;58:1109–17.CrossRef
97.
Mikkelsen KH, Knop FK, Frost M, Hallas J, Pottgard A. Use of antibiotics and risk of type 2 diabetes: a population-based case–control study. J Clin Endocrinol Metab. 2015;100(10):3633–3640.
98.
Thuny F, Richet H, Casalta J-P, Angelakis E, Habib G, Raoult D. Vancomycin treatment of infective endocarditis is linked with recently acquired obesity. PLoS One. 2010;5(2), e9074.PubMedPubMedCentralCrossRef
99.
Trasande L, Blustein J, Liu M, Corwin E, Cox LM, Blaser MJ. Infant antibiotic exposures and early-life body mass. Int J Obes. 2013;37(1):16–23.CrossRef
100.
Bailey LC, Forrest CB, Zhang P, Richards TM, Livshits A, DeRusso PA. Association of antibiotics in infancy with early childhood obesity. JAMA Pediatr. 2014;168(11):1063–9.PubMedCrossRef
101.
Carvalho BM, Guadagnini D, Tsukumo DML, et al. Modulation of gut microbiota by antibiotics improves insulin signalling in high-fat fed mice. Diabetologia. 2012;55(10):2823–34.PubMedCrossRef
102.
Membrez M, Blancher F, Jaquet M, et al. Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerant in mice. FASEB J. 2001;22(7):2416–26.CrossRef
103.
Butler AA, LeRoith D. Minireview: tissue-specific versus generalized gene targeting of the igf1 and igf1r genes and their roles in insulin-like growth factor physiology. Endocrinology. 2001;142:1685–8.PubMedCrossRef
104.
Usala AL, Madigan T, Burguera B, et al. Treatment of insulin-resistant diabetic ketoacidosis with insulin-like growth factor I in an adolescent with insulin-dependent diabetes [Brief report]. N Engl J Med. 1992;327:853–7.PubMedCrossRef
105.
Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes. 1997;46:3–10.PubMedCrossRef
106.
Leung KC, Ho KKY. Stimulation of mitochondrial fatty acid oxidation by growth hormone in human fibroblasts. J Clin Endocrinol Metab. 1997;82:4208–13.PubMed
107.
Goodman HN. The metabolic actions of growth hormone. In: Jefferson LS, Cherrington AD, Goodman HM, editors. Handbook of physiology, section, 7; The endocrine system, vol. 2. The endocrine pancreas and regulation of metabolism. New York: Oxford University Press, Inc.; 2001. p. 849–906.
108.
Vilar L, Naves LA, Costa SS, et al. Increase of classic and nonclassic cardiovascular risk factors in patients with acromegaly. Endocr Pract. 2007;13:363–72.PubMedCrossRef
109.
Munck A, Naray-Fejes-Toth A. Glucocorticoid physiology. In: DeGroot LJ, Jameson LJ, editors. Endocrinology. 5th ed. Philadelphia: Elsevier Saunders; 2006. p. 2287–309.
110.
Salati LM. Regulation of fatty acid biosynthesis and lipolysis. In: Jefferson LS, Cherrington AD, Goodman HM, editors. Handbook of physiology, section, 7; The endocrine system, vol. 2. The endocrine pancreas and regulation of metabolism. New York: Oxford University Press, Inc.; 2001. p. 495–527.
111.
Jefferson LS, Vary TC, Kimball SR. Regulation of protein metabolism in muscle. In: Jefferson LS, Cherrington AD, Goodman HM, editors. Handbook of physiology, section, 7; The endocrine system, vol. 2. The endocrine pancreas and regulation of metabolism. New York: Oxford University Press, Inc.; 2001. p. 536.
112.
Gura T. Pot-bellied mice point to obesity enzyme [News of the Week]. Science. 2001;294:2071–2.PubMedCrossRef
113.
Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science. 2001;294:2166–70.PubMedCrossRef
114.
Qatanani M, Lazar MA. Mechanisms of obesity-associated insulin resistance: many choices on the menu. Genes Dev. 2007;21:1443–55.PubMedCrossRef
115.
Manger WM, Gifford RW. Clinical and experimental pheochromocytoma. 2nd ed. Cambridge: Blackwell Science, Inc.; 1996. p. 209.
116.
Cryer PE. Catecholamines, pheochromocytoma and diabetes. Diabet Rev. 1993;1:309–17.
117.
Pacak K. Preoperative management of the pheochromocytoma patient. J Clin Endocrinol Metab. 2007;92(11):4069–79.PubMedCrossRef
118.
Romero R, Casanova B, Pulido N, et al. Stimulation of glucose transport by thyroid hormone in 3T3-L1 adipocytes: increased abundance of GLUT1 and GLUT4 glucose transporter proteins. J Endocrinol. 2000;164:187–95.PubMedCrossRef
119.
Tosi F, Moghetti P, Castello R, et al. Early changes in plasma glucagon and growth hormone response to oral glucose in experimental hyperthyroidism. Metab Clin Exp. 1996;45:1029–33.PubMedCrossRef
120.
Feng X, Jiang Y, Meltzer P, Yen PM. Thyroid hormone regulation of hepatic genes in vivo detected by complementary DNA microarray. Mol Endocrinol. 2000;14(7):947–55.PubMedCrossRef
121.
Mokuno T, Uchimura K, Hayashi R, et al. Glucose transporter 2 concentrations in hyper- and hypothyroid rat livers. J Endocrinol. 1999;160:285–9.PubMedCrossRef
122.
Kreze Sr A, Kreze-Spirova E, Mikulecky M. Diabetes mellitus in primary aldosteronism. Bratisl Lek Listy. 2000;101:187–90.PubMed
123.
Ferrannini E, Galvan AQ, Santoro D, Natali A. Potassium as a link between insulin and the rennin–angiotensin–aldosterone system. J Hypertens. 1992;10 Suppl 1:S5–S10.CrossRef
124.
Hitomi H, Kiyomoto H, Nishiyama A, et al. Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells. Hypertension. 2007;50:750–5.PubMedCrossRef
125.
Strauch B, Widimsky J, Sindelka G, Skrha J. Does the treatment of primary hyperaldosteronism influence glucose tolerance? Physiol Res. 2003;52(4):503–6.PubMed
Endotext.org http://​www.​endotext.​org/​index.​htm – This is a complete textbook of endocrinology on the web that is available free.
http://​www.​endocrineweb.​com/​index.​html – This is a site designed for patients and their families.
http://​digestive.​niddk.​nih.​gov/​ddiseases/​a-z.​asp – Diseases of the pancreas can be found at this site.
http://​www.​cancer.​gov/​ – This is a wonderful site to look up all of the endocrine tumors by system, body location, or type.
Mayo Clinic Staff. “Primary Aldosteronism.” http://​www.​mayoclinic.​com/​health/​primary-aldosteronism/​DS00563. January 5, 2007. Accessed 16 Feb 2008.

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »